Sterling Pharma Solutions
Katie Crowley currently serves as the Associate Director of Project Management at Sterling Pharma Solutions, overseeing the Project Management Team and driving customer projects within laboratory services and API manufacturing in a GMP environment since November 2023. Prior to this role, Katie held various leadership positions including Associate Director of Project Management at Fortrea from March 2012 to November 2023, and Associate Director in GPLT at Labcorp Drug Development. Experience also includes positions at Covance as Project Director and Senior Project Manager, a Senior Study Manager role at ExecuPharm, and Senior Project Manager at PPD. Katie began a career in clinical research with positions at ICON plc as a Clinical Project Manager and Clinical Research Associate. Educational qualifications include a Bachelor's degree in Human Services/Psychology from the University of Wisconsin–Oshkosh.
This person is not in any teams
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities